Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118112 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL15521126 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29362168 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL31248559 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29352034 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL20592813 | 0.94 | MDM2 (0.51) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL20592811 | 0.94 | MDM2 (0.51) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29759385 | 0.94 | MDM2 (0.51) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29493132 | 0.92 | MDM2 (0.53) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL8226910 | 0.92 | MDM4 (0.50) | MDM4TP53CASP3KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8318717-B2 | Tetrapeptide capable of inhibiting binding of the Smac protein to Inhibitors of apoptosis, thus promoting apoptosis or sensitizing cells; antiproliferative and anticarcinogenic agents | 2CUREX (DK) | 2012-11-27 | — | — | US | disclosed |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-20100068692-A1 | ANTIFREEZE GLYCOPROTEIN ANALOGUES AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2010-03-18 | — | — | US | disclosed |
| US-20090239755-A1 | Identification of Compounds Modifying A Cellular Response | 2CUREX (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20080194537-A1 | Compounds Modifying Apoptosis | 2CUREX (DK) | 2008-08-14 | — | — | US | disclosed |
| US-7335726-B2 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2003017924-A2 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARMACEUTICALS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068692-A1 | ANTIFREEZE GLYCOPROTEIN ANALOGUES AND USES THEREOF | SRRM2, MSR1, CD59 | MDM4 4469/4885TP53 1807/4885CASP3 2146/4885 |
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | MDM4 1748/4885TP53 234/4885CASP3 1340/4885 |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | MDM4 4381/4885TP53 3992/4885CASP3 513/4885 |
| US-20080194537-A1 | Compounds Modifying Apoptosis | API5, BAX, BAD | MDM4 486/4885TP53 32/4885CASP3 14/4885 |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | MDM4 3892/4885TP53 1996/4885CASP3 1359/4885 |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | MDM4 4381/4885TP53 3992/4885CASP3 513/4885 |
| US-20090239755-A1 | Identification of Compounds Modifying A Cellular Response | MCL1, PMAIP1, CDC37 | MDM4 169/4885TP53 18/4885CASP3 473/4885 |
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | NGLY1, LSS, NRDC | MDM4 2534/4885TP53 3035/4885CASP3 1419/4885 |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | MDM4 2125/4885TP53 23/4885CASP3 2201/4885 |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | MDM4 1748/4885TP53 234/4885CASP3 1340/4885 |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | MDM4 1748/4885TP53 234/4885CASP3 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.